Endpoints
tumor, neutropenia, febrile neutropenia, pain, Cancer
ADVERSE EVENT, TUMOR, NEUTROPENIA, FEBRILE NEUTROPENIA, DISEASE COURSE, SECONDARY, CANCER
The primary study endpoint was the incidence and severity of drug‐related AEs. Bone pain was scored daily by two scoring methods.The secondary endpoints were the incidence rate of grade 3/4 neutropenia in each chemotherapy cycle, ANC changes in each chemotherapy cycle, occurrence, and duration of febrile neutropenia (FN) in each chemotherapy cycle (axillary temperature was utilized as standard body temperature, and FN was defined as ANC <0.5 × 10The AEs were assessed according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. AEs occurring after treatment with the study drug, including symptoms, disease course, and laboratory abnormalities, were reported. The correlation between the study drug and AE occurrence was evaluated by the physicians according to a 5‐point scale.In this study, subgroup analysis was performed to examine the differences in the incidence rates of grade 3/4 neutropenia and FN for different tumor types.